I rate Corcept Therapeutics Incorporated Buy with an $82 target; growth opportunities appear underappreciated, and my base case does not require Cushing's approval. CORT Q3 revenue rose 64% to $340.5 million as Korlym grew despite generic competition and Lifyorli gained traction. The December 17 FDA decision and Teva litigation could drive significant volatility; I would size positions cautiously.








